Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 1986Clinical Infectious Diseases

Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute Infection

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJames A. RetsemaPfizer (United States)AEA. R. EnglishTexas Tech UniversityAGAgnès GirardInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Retsema et al. (1986) studied this question.

synapsesocial.com/papers/6a89c99641f4089922bd7674https://doi.org/10.1093/clinids/8.supplement_5.s528
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization1978 · 405 citations
  2. 2Antibiotic Susceptibility of Beta-Lactamase-Producing Strains of Branhamella ( Neisseria ) catarrhalis1980 · 63 citations
  3. 3HR 756, a Highly Active Cephalosporin: Comparison with Cefazolin and Carbenicillin1978 · 71 citations
  4. 4Genetic Control In Methicillin-Resistant Strains Of Staphylococcus Aureus1972 · 51 citations
  5. 5In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria1985 · 65 citations